CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
4/9
Piotroski F — financial health
-1.08
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $6,000 | -$6.0M | $3,806 | — | $7.5M |
| 2024 | $11,000 | -$5.5M | $6,600 | — | $6.3M |
| 2023 | $9,000 | -$5.3M | $5,400 | — | $10.3M |
| 2022 | $88,600 | -$10.1M | $60,109 | — | $15.9M |
| 2021 | $87,754 | $19.2M | $39,805 | — | $10.2M |
| 2020 | $164,500 | -$36.3M | $113,904 | — | -$39.8M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.08 (distress)
- Working capital / assets 0.911
- Retained earnings / assets -9.039
- EBIT / assets -0.787
- Equity / liabilities 26.378
Source: SEC EDGAR filings · CIK 0001187953 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.